Allergan, Vitae Pharma Announce Expiration Of HSR Waiting Period 

The FINANCIAL — Allergan plc and Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company, on October 17 announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), has expired with respect to Allergan’s pending acquisition of Vitae.

The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions.  Both companies expect the transaction to be completed in the fourth quarter of 2016, according to Allergan.